Multiple Myeloma an incurable disease, but I have spent the last 25 years in remission using a blend of conventional oncology and evidence-based nutrition, supplementation, and lifestyle therapies from peer-reviewed studies that your oncologist probably hasn't told you about.
Click the orange button to the right to learn more about what you can start doing today.
It is standard therapy for newly diagnosed multiple myeloma patients who are eligible to undergo an allo BMT. According to studies overall survival is not increased with an ASCT but the study linked and excerpted below does establish that vitamin D deficiency in these patients does result in an increased risk of relapse.
An ASCT may or may not be the right therapy for you depending on your age and stage at diagnosis in my experience. But please read the study linked below and consider supplementing with vitamin D asap.
I have been supplementing with Life Extension Vitamin D for years because Life Extension supplements have been evaluated and approved by consumerlab.com, an independent company.
Please go to the right side of the page, register for and watch the free webinar that explains the Multiple Myeloma Cancer Coaching program. I developed the program after years of research directing PeopleBeatingCancer, the non-profit that I run.
Scroll down the page, post a question or comment and I will reply to you ASAP.
“New data suggests white patients who are deficient in vitamin D have lower rates of survival when diagnosed with multiple myeloma. The phenomenon was not seen, however, in African American patients.
Vitamin D deficiency has been linked with poor survival rates in some patients with multiple myeloma; however, the phenomenon appears to vary based on race.
According to a new study, white patients fare worse in terms of overall survival when they are deficient in vitamin D, but African-American patients do not. The findings are published in the journal Blood Advances.1
“Patients with myeloid malignancies who have vitamin D deficiency prior to allogeneic stem cell transplantation (alloSCT) have an increased risk of relapse, according to a study published in the Journal of Clinical Oncology.…
To determine the prognostic relevance of vitamin D deficiency in this setting, researchers analyzed the outcomes of 492 patients in a training cohort and 398 patients in a validation cohort. Eligible patients had a myeloid or lymphoid malignancy, underwent alloSCT, and had validated records of pre-transplant vitamin D levels…
Vitamin D deficiency was noted in 80% of patients in the training cohort and 87% of patients in the validation cohort prior to allograft. Median follow-up was 51.2 months…”
“Most people do not think about their vitamin D intake, but Chloe Spear, BSN, RN, OCN, knows that it is important – especially for patients with myeloma.
Spear, clinical specialty coordinator in the Myeloma Program at Mount Sinai, conducted a study examining the effects that a vitamin D deficiency can have on outcomes for patients with myeloma. She hopes to turn her findings – that patients with deficiencies have poorer prognoses – into a standard-of-care for treating patients who come into the clinic with vitamin D deficiencies. Intervention would be fairly simple and straightforward: prescribing patients with oral vitamin D supplements to take daily.”